MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium

Phase 2agenT-797Neutral

AI Analysis

Summary

MiNK Therapeutics presented initial observations from an ongoing Phase 2 trial of agenT-797 in patients with severe hypoxemic pneumonia at the 2026 Military Health System Research Symposium.

Clinical Trial Data

Phase

Phase 2

Outcome Details

initial observations from patients treated with agenT-797

Importance:5/10

Sentiment:

0.00

Phase 2iNKT cell therapysevere hypoxemic pneumoniaclinical trialconference presentation

Related Companies

$INKT

Read the original article

Published by GlobeNewswire Clinical Studies on August 6, 2026 4:00 PM

Read Original